These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 16344532)

  • 1. Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism.
    Martignoni E; Cosentino M; Ferrari M; Porta G; Mattarucchi E; Marino F; Lecchini S; Nappi G
    Neurology; 2005 Dec; 65(11):1820-2. PubMed ID: 16344532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients.
    Ferrari M; Martignoni E; Blandini F; Riboldazzi G; Bono G; Marino F; Cosentino M
    Eur J Clin Pharmacol; 2012 Nov; 68(11):1493-9. PubMed ID: 22527346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone].
    Arnold G; Kupsch A
    Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COMT inhibition and safety.
    Martignoni E; Blandini F; Pacchetti C; Nappi G
    Funct Neurol; 2001; 16(4 Suppl):135-40. PubMed ID: 11996508
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and tolerability of COMT inhibitors.
    Brooks DJ
    Neurology; 2004 Jan; 62(1 Suppl 1):S39-46. PubMed ID: 14718679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
    Kaakkola S
    Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Entacapone-induced hepatotoxicity and hepatic dysfunction.
    Fisher A; Croft-Baker J; Davis M; Purcell P; McLean AJ
    Mov Disord; 2002 Nov; 17(6):1362-5; discussion 1397-1400. PubMed ID: 12465084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors.
    Männistö PT
    Adv Pharmacol; 1998; 42():324-8. PubMed ID: 9327906
    [No Abstract]   [Full Text] [Related]  

  • 9. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Harper J; Vieira B
    Lancet; 1998 Aug; 352(9127):578. PubMed ID: 9716090
    [No Abstract]   [Full Text] [Related]  

  • 10. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Henry C; Wilson JA
    Lancet; 1998 Jun; 351(9120):1965-6. PubMed ID: 9654299
    [No Abstract]   [Full Text] [Related]  

  • 11. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.
    Fischer JJ; Michaelis S; Schrey AK; Graebner OG; Glinski M; Dreger M; Kroll F; Koester H
    Toxicol Sci; 2010 Jan; 113(1):243-53. PubMed ID: 19783845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [COMT inhibitors].
    Bornkessel B
    Med Monatsschr Pharm; 1999 May; 22(5):138-41. PubMed ID: 10365553
    [No Abstract]   [Full Text] [Related]  

  • 13. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects.
    Russ H; Müller T; Woitalla D; Rahbar A; Hahn J; Kuhn W
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):719-20. PubMed ID: 10619191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease.
    Nutt JG
    Lancet; 1998 Apr; 351(9111):1221-2. PubMed ID: 9643737
    [No Abstract]   [Full Text] [Related]  

  • 15. COMT inhibition with entacapone in the treatment of Parkinson's disease.
    Rinne UK; Gordin A; Teräväinen HT
    Adv Neurol; 1999; 80():491-4. PubMed ID: 10410761
    [No Abstract]   [Full Text] [Related]  

  • 16. Issues important for rational COMT inhibition.
    Dingemanse J
    Neurology; 2000; 55(11 Suppl 4):S24-7; discussion S28-32. PubMed ID: 11147507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COMT inhibitors and liver toxicity.
    Watkins P
    Neurology; 2000; 55(11 Suppl 4):S51-2; discussion S53-6. PubMed ID: 11147510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations.
    Spahr L; Rubbia-Brandt L; Burkhard PR; Assal F; Hadengue A
    Dig Dis Sci; 2000 Sep; 45(9):1881-4. PubMed ID: 11052337
    [No Abstract]   [Full Text] [Related]  

  • 19. Tolcapone improves cognition and cortical information processing in normal human subjects.
    Apud JA; Mattay V; Chen J; Kolachana BS; Callicott JH; Rasetti R; Alce G; Iudicello JE; Akbar N; Egan MF; Goldberg TE; Weinberger DR
    Neuropsychopharmacology; 2007 May; 32(5):1011-20. PubMed ID: 17063156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolcapone for Parkinson's disease.
    Med Lett Drugs Ther; 1998 Jun; 40(1028):60-1. PubMed ID: 9629124
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.